Dark

Check out our Dark Pool Levels

ATXS
Astria Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

Jan 22, 2026

12.58USD+0.640%(+0.08)3,199,309

Pre-market

0.00USD-100.000%(-12.50)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

08:19AM EST Astria Therapeutics Q3 Loss Per Share $0.61 Vs Loss $3.36 Prior Year RTTNews

08:16AM EST Astria Therapeutics Q3 EPS $(0.61) Beats $(0.77) Estimate Benzinga

08:00AM EST Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update Business Wire

04:09AM EST Earnings Scheduled For November 10, 2021 Benzinga

Nov 9, 2021

08:00AM EST Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference Business Wire

Nov 5, 2021

09:42AM EDT Astria Therapeutics Highlights Presentation Of Preclinical Data Showing Differentiated Profile Of STAR-0215, I Development To Treat Hereditary Angioedema Benzinga

08:00AM EDT Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema Business Wire

Oct 27, 2021

08:00AM EDT Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10 Business Wire

Oct 21, 2021

12:11PM EDT Astria Therapeutics To Present New STAR-0215 Preclinical Results At The 2021 American College of Allergy, Asthma And Immunology Annual Scientific Meeting Benzinga

Oct 18, 2021

08:13AM EDT Astria Therapeutics Presents Findings On Burdens Of Disease And Treatment In Hereditary Angioedema RTTNews

08:04AM EDT Astria Therapeutics Highlights Presentation Of Findings An Burdens Of Disease And Treatment In Hereditary Angioedema At 2021 NORD Rare Diseases And Orphan Products Breakthrough Summit Benzinga

08:00AM EDT Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit Business Wire

Oct 12, 2021

08:06AM EDT Astria Therapeutics To Present Findings On Burdens Of Disease And Treatment In Hereditary Angioedema At 2021 NORD Rare Diseases And Orphan Products Breakthrough Summit Benzinga

Sep 29, 2021

10:12AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2021 Benzinga

09:21AM EDT Jefferies Initiates Coverage On Astria Therapeutics with Buy Rating, Announces Price Target of $20 Benzinga

Sep 10, 2021

08:00AM EDT Astria Therapeutics to Present at Upcoming Investor Conferences Business Wire

Share